C4 Therapeutics (CCCC) filed a shelf registration statement with the US Securities and Exchange Commission on late Friday for the potential sale of up to $400 million in securities, to be offered from time to time.
The filing covers common stock, preferred stock, debt securities, warrants and units.
The company said the offering proceeds will be used primarily to support research and development, and operations, with flexibility for other corporate purposes as needed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments